Short Interest in Xenetic Biosciences, Inc. (NASDAQ:XBIO) Decreases By 55.0%

Xenetic Biosciences, Inc. (NASDAQ:XBIO) saw a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 20,320 shares, a decline of 55.0% from the August 15th total of 45,169 shares. Approximately 1.0% of the shares of the company are short sold. Based on an average daily trading volume, of 31,148 shares, the short-interest ratio is currently 0.7 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC acquired a new position in Xenetic Biosciences, Inc. (NASDAQ:XBIO) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 15.12% of the company’s stock.

Xenetic Biosciences Stock Up 1.7%

NASDAQ XBIO traded up $0.07 during midday trading on Monday, hitting $3.96. The company had a trading volume of 9,240 shares, compared to its average volume of 27,945. The stock has a market cap of $9.08 million, a price-to-earnings ratio of -3.42 and a beta of 2.23. The firm has a fifty day simple moving average of $3.29 and a two-hundred day simple moving average of $3.08. Xenetic Biosciences has a fifty-two week low of $1.90 and a fifty-two week high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter. Xenetic Biosciences had a negative return on equity of 40.62% and a negative net margin of 75.90%.The company had revenue of $0.66 million for the quarter.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.